We now made use of these findings and compared the opposite microglia signatures upon loss of TREM2 or GRN function on the proteome level in human and mouse models to explore potential markers for microglia activation and confirmed the translational applicability of our findings in CSF of AD and FTD-GRN patients. The gene discussed is TREM2; the disease is frontotemporal dementia.